You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

human bispecific full length IgG antibody, CLEC12A, CD3

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myelogenous Leukemia, Acute Myeloid Leukemia Trial in Worldwide (MCLA-117 bispecific antibody)

Active, not recruiting
  • Acute Myelogenous Leukemia
  • Acute Myeloid Leukemia
  • MCLA-117 bispecific antibody
  • Augusta, Georgia
  • +9 more
May 6, 2021

Dose Escalation Part: Locally Advanced or Metastatic Solid Tumor(s), Expansion Part: Prostate Cancer, Expansion Part: Esophageal

Terminated
  • Dose Escalation Part: Locally Advanced or Metastatic Solid Tumor(s)
  • +7 more
  • GEN1044 is an IgG1 bispecific antibody targeting CD3 and 5T4.
  • Nashville, Tennessee
  • +5 more
Mar 1, 2022

AML, Childhood Trial in United States (CD33*CD3 BsAb)

Active, not recruiting
  • AML, Childhood
  • CD33*CD3 BsAb
  • Birmingham, Alabama
  • +12 more
Jan 12, 2023

Advanced Solid Tumors Trial in Guangzhou (MR001)

Not yet recruiting
  • Advanced Solid Tumors
  • Guangzhou, Guangdong, China
    Nanfang Hospital, Southern Medical University
Nov 12, 2023

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Richter's Transformation
  • Boston, Massachusetts
  • +1 more
Sep 12, 2023

Lymphoma, Lymphoma, Large B-Cell, Diffuse Trial in Boston (Glofitamab, Polatuzumab, Rituximab)

Not yet recruiting
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Boston, Massachusetts
  • +1 more
Apr 4, 2023

Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma Trial in Worldwide (AZD5863)

Recruiting
  • Gastric Cancer
  • +3 more
  • Jacksonville, Florida
  • +16 more
Aug 17, 2023

HIV-1-infection Trial in Mbeya (ART, 10E8.4/iMab, VRC07-523LS)

Not yet recruiting
  • HIV-1-infection
  • Mbeya, Tanzania
    National Institute for Medical Research-Mbeya Medical Resarch Ce
Jun 6, 2023

Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC) Trial (PT217)

Not yet recruiting
  • Small Cell Lung Cancer (SCLC)
  • +3 more
  • (no location specified)
Dec 7, 2022

Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer Trial in Detroit (biological,

Completed
  • Metastatic Pancreatic Adenocarcinoma
  • +3 more
  • Aldesleukin
  • +9 more
  • Detroit, Michigan
    Wayne State University/Karmanos Cancer Institute
Mar 30, 2022

Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult Trial in Boston (Epcoritamab, Rituximab)

Not yet recruiting
  • Follicular Lymphoma
  • Low Grade Non-Hodgkin's Lymphoma, Adult
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Mar 13, 2023

SCLC Trial in United States (Nivatrotamab)

Terminated
  • SCLC
  • Tampa, Florida
  • +6 more
Jul 11, 2022

Multiple Myeloma Trial in Worldwide (Elranatamab (PF-06863135))

Active, not recruiting
  • Multiple Myeloma
  • Elranatamab (PF-06863135)
  • Beverly Hills, California
  • +75 more
Oct 4, 2022

AML, MDS Trial in Houston (Vibecotamab, Dexamethasone, Acetaminophen)

Recruiting
  • AML
  • MDS
  • Houston, Texas
    M D Anderson Cancer Center
Sep 29, 2022

B-Cell Lymphoma Trial in Heidelberg, Melbourne, Nedlands (TG-1801, Ublituximab)

Active, not recruiting
  • B-Cell Lymphoma
  • Heidelberg, Victoria, Australia
  • +2 more
Jan 20, 2023

Esophagus Cancer Trial in Guangzhou (Cadonilimab, Paclitaxel and cisplatin, intensity-modulated radiotherapy)

Not yet recruiting
  • Esophagus Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University
Nov 20, 2023

Multiple Myeloma Trial in Montréal (Elranatamab)

Not yet recruiting
  • Multiple Myeloma
  • MontrĂ©al, Quebec, Canada
    McGill University Health Centre
Sep 21, 2023

NSCLC, Solid Tumor Trial in Tianjin (HS-20117)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Solid Tumor
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Jul 10, 2023

Adult Patients Treated in Study R5459-RT-1944 Who Receive A

Not yet recruiting
  • Chronic Kidney Disease (CKD)
  • Noninterventional
  • (no location specified)
Nov 21, 2022

Hematological Malignancies Trial in Worldwide (Teclistamab)

Recruiting
  • Hematological Malignancies
  • Birmingham, Alabama
  • +80 more
Jan 27, 2023

Lung Cancer Squamous Cell Trial in Stuttgart, Tuebingen (CC-1 and Toczilizumab)

Recruiting
  • Lung Cancer Squamous Cell
  • CC-1 and Toczilizumab
  • Stuttgart, BW, Germany
  • +1 more
Feb 2, 2022

Advanced Breast Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer,

Withdrawn
  • Advanced Breast Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer
  • cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Colorectal Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer,

Withdrawn
  • Advanced Colorectal Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer
  • Cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Pancreatic Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer,

Withdrawn
  • Advanced Pancreatic Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer
  • cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020